PYC Therapeutics Limited (AU:PYC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PYC Therapeutics (ASX:PYC) is advancing its VP-001 drug candidate, aimed at treating Retinitis Pigmentosa type 11, with promising results from its Phase 1/2 clinical trials showing improved vision in patients. The company is gearing up for discussions with the FDA to initiate a registrational trial in 2025, signaling a significant step towards addressing a market valued at over $1 billion annually. This development is part of PYC’s broader strategy to deliver first-in-class RNA therapies for genetic diseases.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.